ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) will hold its 3Q20 earnings conference call with the financial community on 4th November 2020 at 4:30 PM Eastern Time.
The conference call will be webcast live on Internet at www.acadia-pharm.com
Earnings Expectation
ACADIA Pharmaceuticals Inc. is reporting third quarter earnings results on Wednesday 4th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.38 per share from $ 118.82 million in revenue. For the full year, analysts predict revenues of $ 443.75 million, while looking forward to loss of $ 1.66 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 430.00 million ~ $ 450.00 million
Click Here For More Historical Outlooks Of ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder.
